Otitis media with effusion (OME) is common and may cause hearing loss with associated delayed language development in children. Treatment remains controversial.
To examine evidence for or against treating OME with systemic or topical nasal steroids.
We searched the Cochrane Controlled Trials Register using the terms otitis media; otitis media with effusion; glue ear; or OME and steroids; glucocorticoids; glucocorticoids, synthetic; glucocorticoids, topical; or anti-inflammatory agents, steroidal; or various combinations of these terms. EMBASE and MEDLINE were also searched.
Randomized controlled trials of oral and topical nasal steroids, either alone or in combination with another agent such as an antibiotic, were included. Ten studies met the inclusion criteria.
Data extraction and methodological quality assessment were performed by the 2 of us (C.C.B. and J.H.v.d.V.) independently, using standardized methods described in the Cochrane Collaboration Handbook.
The odds ratio for OME persisting after short-term follow-up in children treated with oral steroids compared with a control was 0.22 (95% confidence interval, 0.08 = 0.63), and was 0.32 (95% confidence interval, 0.20 = 0.52) for children treated with oral steroids plus an antibiotic compared with a control plus an antibiotic. Trends favored steroids for most other comparisons, but confidence intervals included unity. Trends favored steroids for most other comparisons, but confidence intervals included unity.
Steroids alone or combined with an antibiotic lead to a quicker resolution of OME in the short-term. However, there is no evidence for a long-term benefit from treating hearing loss associated with OME with either oral or topical nasal steroids. These treatments are, therefore, not recommended.
OTITIS MEDIA with effusion (OME), or "glue ear," is characterized by an accumulation of fluid in the middle ear, in the absence of acute inflammation.1 Otitis media with effusion is the most common cause of acquired hearing loss (HL) in childhood and may negatively affect language development.2,3 The reason why the condition develops is uncertain, but a low-grade infection, poor eustachian tube function, and adenoidal infection or hypertrophy have all been implicated.4 Otitis media with effusion has a prevalence of about 20% at around the age of 2 years, with another peak at the age of 6 years, and often resolves spontaneously.5 The prevalence of recurrent otitis media may be increasing.6
The total annual cost of treating children younger than 5 years for OME is more than $5 billion annually in the United States.7 The insertion of ventilation tubes is the second most common surgical procedure performed on children in the United States. In England and Wales, expenditure by the National Health Service on surgical treatment for OME is around $47.8 million.8 Otitis media with effusion is a common reason for prescribing antibiotics, which contributes to the growing problem of bacterial resistance. The optimal treatment strategy remains controversial, and there is wide international variability in clinical practice.
There is in vitro and animal model evidence that steroids modulate effusions.9- 11 It is hypothesized that steroids could clear effusions by (a) stabilizing membrane phospholipid breakdown and, thus, preventing the formation of arachidonic acid and associated inflammatory mediators; (b) shrinking peritubal lymphoid tissue; (c) enhancing secretion of eustachian tube surfactant; and (d) reducing middle ear fluid viscosity.12 Topical intranasal steroids may be safer than systemic preparations because the glucocorticoid is rapidly degraded in the nasal mucosa to less active metabolites and any unchanged drug that is absorbed is metabolized in the first pass through the liver.13 Systemic adverse effects are, therefore, less likely, while the desired anti-inflammatory effects may be similar. However, systemic steroids may be able to gain access to the middle ear, while topical nasal steroids would not be expected to reach the middle ear but may modulate eustachian tube function. Clinicians may be concerned about using systemic steroids for what may be a self-limiting condition.
This review determines the beneficial and harmful effects of treatment with steroids (systemic and intranasal) for children with OME. Our a priori hypothesis was that steroids (systemic or intranasal), either alone or in combination with another agent, are effective in treating the HL associated with OME and in resolving effusions in children. A more detailed review is published in the Cochrane Review on CD-ROM.14
Randomized controlled trials of oral and intranasal steroids were included. Randomized studies that used nonintervention controls were included, in which blinding of outcome assessment was adequate. Excluded were publications in abstract form, only because adequate appraisal was not possible15,16; uncontrolled nonrandomized17,18 or retrospective studies; and studies reporting outcomes only with ears (rather than children) as the unit of analysis,19,20 because observations made on the ears of a single child cannot be regarded as independent. Studies21 of treatment effect on OME using the ear as the unit of analysis have found larger treatment effects than studies analyzing at the level of the child. Studies (or data from arms of studies)22,23 comparing steroid plus additional treatment with placebo plus placebo were excluded because it was not possible to identify the "steroid effect" from such data.
The focus was on studies of children up to the age of 12 years diagnosed as having unilateral or bilateral OME and who had significant HL, however defined. We report when older subjects were included.
The studies were divided into subgroups according to the following ways of assessing exposure:
1. The diagnosis of OME was defined by (a) an air-bone gap of 10 dB or more, (b) 2 or more of otomicroscopy readings with or without pneumatic otoscopy readings or tympanometry readings, (c) one of an otoscopy reading or a tympanometry reading alone, or (d) poorly or not defined.
2. Significant HL was (a) defined by pure tone audiometric HL of more than 20 dB at 2 or more times within 3 months; (b) defined, but less strict than a; or (c) uncertain or not defined.
The intervention was systemic or intranasal steroids compared with control (placebo or nonintervention control). Additional treatments, such as antibiotics, were included as long as they were identical in the treatment and the control groups.
We examined studies for data on the effect of steroid treatment over time or at multiple points for (1) differences in hearing level, (2) degree of conductive HL, (3) presence or absence of fluid in the middle ear cavity (short- and longer-term), and (4) possible adverse effects.
We also examined studies for the effect of steroid treatment on secondary development outcomes, such as language development and behavior.
We searched the Cochrane Controlled Trials Register in February 2000 using the following search strategy: (1) otitis media (MEDLINE Medical Subject Heading [MeSH] term, including all subheadings); (2) otitis media with effusion (MeSH term, including all subheadings); (3) glue ear (free-text term); (4) OME (free-text term); (5) (1), (2), (3), or (4); (6) steroids (MeSH term, including all subheadings); (7) glucocorticoids (MeSH term, including all subheadings); (8) glucocorticoids, synthetic (MeSH term, including all subheadings); (9) glucocorticoids, topical (MeSH term, including all subheadings); (10) anti-inflammatory agents, steroidal (MeSH term, including all subheadings); (11) (6), (7), (8), (9), or (10); or (12) (5) and (11).
Additional information was identified by searching MEDLINE and EMBASE, using a similar search strategy. We also wrote to experts asking about knowledge of additional studies. Previous systematic reviews and references of trials identified by the search strategy were checked for additional relevant references. There was no language restriction. Searches were carried out by the 2 of us (C.C.B. and J.H.v.d.V.) independently. The full texts of all studies loosely meeting the inclusion criteria were independently assessed by us, and differences of opinion regarding inclusion were resolved by consensus.
Data concerning methods, participants, interventions, and outcomes were extracted from the published reports by the 2 of us (C.C.B. and J.H.v.d.V.) independently, using standardized data extraction forms. Disagreement was resolved by consensus after returning to the original publication. In studies that provided data for various definitions of cure, data for the strictest definition were used. In trials with a crossover design, data from the postcrossover treatment period were not used because observations on patients in treatment periods of these studies cannot be considered independent and carryover effects of treatment periods are likely. Similarly, in multiarm studies (eg, steroid vs antibiotic vs nonsteroidal anti-inflammatory vs control), only data for the steroid-treated and control groups were used.
The methodological quality of the included studies was independently assessed by the 2 of us (C.C.B. and J.H.v.d.V.) using the scheme described in the Cochrane Collaboration Handbook.24 This involved assessing studies for (1) selection bias, (2) performance bias, (3) attrition bias, and (4) detection bias. A 3-point rating scale for overall validity was used, with the grading as follows: (a) low risk of bias—plausible bias is unlikely to alter the results seriously, (b) moderate risk of bias—plausible bias raises some doubt about the results, and (c) high risk of bias—plausible bias seriously weakens confidence in the results.
We used the statistical methods for dichotomous outcomes described by Yusuf and colleagues.25 Results were expressed as an odds ratio for achieving the outcome in question at a given point together with the 95% confidence intervals for this estimate. Continuous data were analyzed using the weighted mean difference in a fixed-effects model. Tests for heterogeneity between studies were performed using a Mantel-Haenszel approach.
Regarding ascertainment of the presence of OME, most studies documented effusions by a combination of pneumatic otoscopy and tympanometry (1b). No study documented HL from OME 2 or more times in the 3 months before study enrollment (2a). (Explanations of 1b and 2a are given in the "Types of Participants" subsection of the "Criteria for Considering Studies" section.) Only one study26 required documented HL for all children before study enrollment. One trial27 was open, comparing children treated with steroids with nonintervention controls.
Four included studies26,28- 30 provided audiometric data at follow-up. However, only one26 provided data that could be used in this review (numbers of children improving their HL by at least 10 dB). Audiometric data otherwise used ears as the unit of analysis or were unclear. No study reported effects on language or other aspects of development.
The adverse effects of steroid treatment were reported in 5 studies.13,23,27,31,32
In cases in which the same data are apparently published twice,27,33- 35 these data are used only once in this review.
Studies fell into 4 categories (oral steroid vs control, oral steroid plus antibiotic vs control plus antibiotic, intranasal steroid vs control, and intranasal steroid plus antibiotic vs control plus antibiotic or antibiotic alone) (Table 1). The study13 of intranasal steroid plus antibiotic vs control plus antibiotic also reported on symptoms in the form of a scale, which was considered as continuous data. This was the only study13 to report symptoms as an outcome, but validation of their symptom scale was not described.
Of the 10 included studies,13,26- 32,34,36 there were 313,26,28 that were rated A for quality. All other studies were rated B, apart from 227,30 that were rated C for quality (Table 2).
Overall, the number of studies for each comparison was small (Table 1). The number of participants available for each comparison ranged from 15 to 274. For the 4 groups of studies, a total of 10 comparisons were made. This reflects the use of various points and methods to measure outcomes. Three included studies26,27,36 provided data for 108 patients randomized to treatment with oral steroid vs control. The odds ratio for OME persisting after short-term follow-up (≤2 weeks) was 0.22. Four included studies28,29,31,34 provided data on a total of 274 patients randomized to treatment with oral steroid plus antibiotic vs control plus antibiotic. The odds ratio for OME persisting after short-term follow-up (≤2 weeks) was 0.32. There was significant heterogeneity between the studies involving steroids plus antibiotics (P<.01). Only one of these studies31 reported longer-term outcomes and provided data for only 15 patients. Seven comparisons across the study groups included only one study, so they offer no new information. Overall, 7 comparisons favored steroids, 2 favored controls, and 1 favored neither. However, the confidence intervals were generally wide and included unity for all but 2 comparisons. Because of the small number of studies in many of the comparisons, we did not perform sensitivity analyses.
No serious or lasting adverse effects were reported in the 4 studies mentioning adverse effects.
Steroids alone or together with an antibiotic appear to improve resolution of effusion in the short-term. However, there was significant heterogeneity between studies involving steroids plus antibiotics. This could be explained by differences between studies in pharmacological interventions, including steroid formulation, steroid dose, duration of steroid treatment, and type and duration of concomitant antibiotic. Also, studies differed in terms of study population, including age, setting, proportion with bilateral OME, and duration of OME at study enrollment. The clinical significance of this finding is uncertain because we were not able to evaluate the effect of steroid treatment on hearing from these studies. Few data are available for longer-term outcomes, and no study assessed the effect of steroids on language in the longer-term. One study27 did assess hearing at 12 months, but this assessment was made on only 35% of the patients, so the results are difficult to interpret and were, therefore, not presented. Given concern about treating what is often a self-limiting condition with systemic steroids, we were particularly interested to examine evidence for the effect of topical nasal steroids. The one study32 we included of intranasal steroid vs placebo showed no benefit. The one study13 of intranasal steroid in combination with an antibiotic demonstrated an effect in clearing effusions in the short-term, but by 3 months, differences between study groups were no longer statistically significant. Adverse effects of steroid treatment were mentioned in a few studies. No study documented HL prospectively before study enrollment. Only one study13 attempted to measure the effect of steroids on subjective symptoms.
Previous reviews1,37,38 were published before the trial by Hemlin and colleagues.31 Some used different inclusion criteria (eg, Nuss and Berman37 included trials published in abstract form only and a nonrandomized open study). However, conclusions were similar to ours in that despite evidence for a short-term steroid effect, the general use of steroids for OME was not recommended. A cost-effectiveness review concluded that steroid plus antibiotic was the most cost-effective intervention for children found to have OME at a first follow-up visit 6 weeks after the diagnosis of acute otitis media.39 However, adverse effects were not considered.
There is imperfect evidence demonstrating short-term improvement in OME from oral steroids alone or combined with an antibiotic. However, we found no evidence for lasting benefit from oral or topical nasal steroid treatment of HL associated with OME. Based on the research we identified, these treatments are, therefore, not recommended.
Otitis media with effusion may be present without significant HL. Positive predictive values range from 49% to 66.4% for an HL of 25 dB or greater after an abnormal tympanogram.40- 42
Given the high rate of spontaneous remission, future studies should document HL associated with OME for a period before beginning study treatment and at follow-up. In the absence of evidence that unilateral OME influences language development, the practice of enrolling children with unilateral OME into treatment studies is questionable. Follow-up should be longer and ideally include symptom, hearing, and language development outcome assessments. Audiometric data should be presented not as mean hearing levels for groups but as numbers of children with defined levels of HL in their best hearing ear. Data should not be presented only with ears as the unit of analysis because observations on the different ears of the same child cannot be regarded as independent. Assessors of outcomes should be blinded to the treatment condition. Improvement should be clearly defined (eg, researchers should present data for children with bilateral OME resolving in one but not both ears). Analysis should be based on the intention to treat. A short course of oral steroids followed by longer-term intranasal steroids has so far not been evaluated.
Accepted for publication December 1, 2000.
This study was supported by a fellowship from the Wales Office of Research and Development for Health and Social Care, National Health Service (Dr Butler).
We thank the editorial staff and the editorial group of the Cochrane Ear, Nose and Throat Disorder Group for their help and comments. Comments from external and internal reviewers of the Cochrane Ear, Nose and Throat Disorder Group on the longer version of this review, which appears in the Cochrane Database of Systematic Reviews, are gratefully acknowledged.
Corresponding author: Christopher C. Butler, BA, MB, ChB, DCh, MRCGP, CCH, MD, Department of Family Medicine, McMaster University, Faculty of Health Sciences, 1200 Main St W, HSC–2V14, Hamilton, Ontario, Canada L8N 3Z5 (e-mail: email@example.com).
Butler CC, van der Voort JH. Steroids for Otitis Media With EffusionA Systematic Review. Arch Pediatr Adolesc Med. 2001;155(6):641-647. doi:10.1001/archpedi.155.6.641